J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Pozycja w akcjach
#3897
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Cena akcji
$26.58
Ostatnia synchronizacja: 2026-07-23
Kapitalizacja rynkowa
$4.24B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
38.40%
Kraj
IN
Handel J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategoria
Healthcare
Przychody dla J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Przychody w Mar 2026 TTM: $457.75M
Według najnowszych raportów finansowych J. B. Chemicals & Pharmaceuticals Limited, obecny przychód firmy (TTM) wynosi $457.75M. W roku 2024 firma osiągnęła przychód w wysokości $417.85M wzrost w porównaniu do przychodu z roku 2023, który wynosił $379.23M. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy J. B. Chemicals & Pharmaceuticals Limited od 2005 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $457.75M | -0.08% |
| 2025 | $458.10M | 9.63% |
| 2024 | $417.85M | 10.19% |
| 2023 | $379.23M | 18.75% |
| 2022 | $319.36M | 16.55% |
| 2021 | $274.01M | 18.45% |
| 2020 | $231.33M | -0.24% |
| 2019 | $231.89M | 9.00% |
| 2018 | $212.73M | 5.28% |
| 2017 | $202.07M | 14.60% |
| 2016 | $176.33M | 4.91% |
| 2015 | $168.07M | 7.33% |
| 2014 | $156.59M | 8.27% |
| 2013 | $144.63M | -8.54% |
| 2012 | $158.14M | -16.27% |
| 2011 | $188.85M | 14.47% |
| 2010 | $164.98M | 16.80% |
| 2009 | $141.25M | 0.50% |
| 2008 | $140.54M | 15.92% |
| 2007 | $121.24M | 15.95% |
| 2006 | $104.56M | 27.21% |
| 2005 | $82.19M | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,344.40% |
IN
|
